Actively Recruiting

Phase Not Applicable
Age: 1Year +
All Genders
ID07243249

Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing in the General Population in Community Settings

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-14

2000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Respiratory infections caused by viruses such as influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) are common, especially during winter. These illnesses often have symptoms that make it hard to tell if the infection is viral or bacterial, leading to frequent antibiotic prescriptions even when not necessary. Excessive antibiotic use contributes to bacterial resistance, a serious public health concern. This study aims to evaluate whether using a rapid test called TROD, which quickly detects these viruses, can reduce unnecessary antibiotic prescriptions in community settings during the 2025-2026 autumn-winter season. The study involves two periods for each participating doctor: first, a control period where doctors treat patients without using the TROD test, and second, an intervention period where doctors use the TROD test on patients. Each period includes 10 patients who meet the eligibility criteria. The TROD test uses a nasal swab to identify SARS-CoV-2, influenza viruses, and RSV in under 15 minutes. Doctors may prescribe antibiotics based on usual practice during the control period, and with guidance from the TROD test results during the intervention period. Participants will be monitored for antibiotic prescriptions from the day of consultation to 14 days later. Researchers will collect data on antibiotic use, re-consultations, hospitalizations, and test accuracy compared to standard PCR tests. Patient characteristics and doctors’ practices will also be studied. The research aims to assess how the TROD test impacts antibiotic prescribing, viral infection detection, and healthcare costs, supporting efforts to reduce antibiotic resistance.

CONDITIONS

Brief Title

Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing

Who Can Participate

Age: 1Year +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 1 year or older
  • Presenting with fever over 38°C within the past 72 hours and at least one of the following symptom combinations: rhinorrhea and/or nasal obstruction with cough; body aches, cough, and fatigue; sore throat with negative strepto-test; cough alone; or ear pain
  • Or suspicion of lower respiratory tract infection with signs such as respiratory rate over 20/min, heart rate over 100/min, fatigue, body aches, chills, or fever along with cough, sputum, chest pain, or abnormal lung sounds
  • Affiliation with the national health insurance system
  • Informed consent from adult participant or guardian for minors
Not Eligible

You will not qualify if you...

  • Requirement for hospitalization
  • Presence of a non-respiratory infection requiring antibiotic treatment
  • Patients covered by State Medical Aid (AME)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Control Period

Duration - Period covering inclusion and 14 days after

Participants are observed without the use of triplex rapid diagnostic tests (TROD), and doctors may prescribe antibiotics as usual based on clinical judgment.

1 initial visit plus follow-up assessments up to 14 days

Intervention Period

Duration - Period covering inclusion and 14 days after

Participants undergo testing with triplex rapid diagnostic tests (TROD) for SARS-CoV-2, influenza, and RSV during consultation, which may influence antibiotic prescribing decisions.

1 initial visit with TROD testing plus follow-up assessments up to 14 days

Trial Site Locations

Total: 1 location

1

Assistance Publique - Hôpitaux de Paris

Garches, France

Actively Recruiting

Loading map...

Research Team

A

Aurélien DINH, MD, PhD

J

Jacques ROPERS, PharmD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

FACTORIAL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Similar Trials

Estimating the Risk for and Severity of Respiratory Infectio...

Carrier State

Actively Recruiting

1 location

To Determine the Efficacy of Irrisept in Reducing Urinary Tr...

Urinary Tract Infection

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here